Health Trials

Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development

ConditionColorectal Polyp
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorInstituto de Investigación Sanitaria Aragón

About this trial

Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy

Eligibility criteria

Qualifiers

At least 10 adenomas

At least 5 proximal serrated polyps (PSP)

At least 2 serrated polyps with diameters ≥10 mm

Serrated Polyposis Syndrome (SPS)

Disqualifiers

History of allergic reaction attributed to compounds of similar chemical composition to the study agents.

Incomplete colonoscopy or with poor quality criteria, Boston <6.

Concomitant acetylsalicylic acid (ASA), NSAIDs, misoprostol, corticosteroids or statins needed on a regular or predictable basis during the time of the study.

Previous gastrointestinal surgery (colon or small intestine or gastric) that affects the absorption of nutrients.

Trial design

Treatments tested in this trial

  • Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
  • Conventional milk
  • Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
  • Conventional yogurt
  • Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
  • Conventional fresh cheese

Treatment groups

34 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Instituto de Investigación Sanitaria Aragón

Lead sponsor

Cooperativas Lacteas Unidas

Collaborator

Hospital Clínico Universitario Lozano Blesa

Collaborator

Source ClinicalTrials.gov